SXTP

#5000
60 Degrees Pharmaceuticals, Inc. - Common Stock
1.0 3 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.03
1.03
Intervallo Annuale
0.34
8.62
Variazione giornaliera
-2.83%
Variazione Mensile
-12.71%
Variazione di 6 mesi
-66.01%
Variazione Annuale
-26.43%
Chiusura Precedente
1.0 6
Open
1.0 3
Minimo
1.0 3
Massimo
1.0 3
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
60 DEGREES PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
60 DEGREES PHARMACEUTICALS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
60 DEGREES PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K

60 DEGREES PHARMACEUTICALS, INC. current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by 60 Degrees Pharmaceuticals, Inc. on May 13, 2026. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols SXTP (Common Stock) and SXTPW (Warrants). The filing identifies the registrant as an emerging growth company.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.

Material Changes

The primary material change reported is the appointment of a new Board member:

  • Appointment: On May 13, 2026, the Board appointed Eric Francois as a member of the Board of Directors, effective immediately.
  • Background: Mr. Francois is a strategic financial executive with over 20 years of experience in healthcare and life sciences. His background includes roles as Managing Director at Raymond James and Credit Suisse, and previously as CFO of SCYNEXIS, Inc., where he raised over $300 million in capital.
  • Current Roles: He currently serves as an Independent Director of CERo Therapeutics Holdings, Inc. and as an independent strategic advisor to emerging life sciences companies.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, outlook, or specific risk factors related to operations. Regarding the new appointment:

  • Compensation: Mr. Francois will receive compensation consistent with the Company's standard arrangements for non-employee directors.
  • Conflicts of Interest: The Company states there are no arrangements or understandings between Mr. Francois and other persons regarding his appointment, no family relationships with existing directors or officers, and no direct or indirect material interest in transactions requiring disclosure.

Investor Verification Checklist

  • Verify the effective date of Eric Francois's appointment (May 13, 2026) and his specific committee assignments, if any.
  • Review the Company's standard compensation arrangements for non-employee directors to understand the financial impact of this appointment.
  • Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
  • Check subsequent filings for any updates to the Board composition or related party transactions involving Mr. Francois.

Notizie